OneAscent Family Office LLC Buys Shares of 4,802 Gilead Sciences, Inc. $GILD

OneAscent Family Office LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel reports. The fund purchased 4,802 shares of the biopharmaceutical company’s stock, valued at approximately $607,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Paulson Wealth Management Inc. grew its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. lifted its stake in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares in the last quarter. Davidson Trust Co. boosted its holdings in Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC boosted its holdings in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the period. Finally, Financial Connections Group Inc. grew its position in Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GILD. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Wednesday, May 20th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Needham & Company LLC restated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Finally, Daiwa Securities Group reduced their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the sale, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,000 shares of company stock worth $10,837,860 over the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $143.44 on Friday. The stock’s 50-day moving average is $131.56 and its two-hundred day moving average is $136.52. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a market cap of $177.86 billion, a price-to-earnings ratio of -53.72 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter last year, the company earned $2.01 EPS. Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post -0.51 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.